|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data provided no evidence that PAF-AH polymorphisms influence PAF-AH activity and atherosclerosis in hypercholesterolemic Sicilian patients.
|
15364890 |
2004 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Since rs10846744 has been reported in association with Lp-PLA2 mass and activity, we hypothesized that inflammatory pathways might mediate the association of rs10846744 with atherosclerosis.
|
30289950 |
2018 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to investigate whether Lp-PLA2 is related to subclinical atherosclerosis, independently from traditional risk factors, in a general Japanese population by analyses of both the observational study and Mendelian randomization using V279F polymorphism.
|
26775119 |
2016 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study.
|
19034521 |
2009 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A single nucleotide polymorphism in the plasma PAF acetylhydrolase gene and risk of atherosclerosis in Japanese patients with peripheral artery occlusive disease.
|
16650870 |
2006 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein-associated phospholipase A2 (Lp-PLA<sub>2</sub>) levels are associated with the development of atherosclerosis.
|
27905470 |
2016 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined the association of LpPLA2 activity and ApoC3 LOF mutations and incident cardiovascular disease (CVD) (defined as coronary heart disease [CHD] plus ischemic stroke) and all-cause mortality in the biracial longitudinal Atherosclerosis Risk In Communities (ARIC) study.
|
26117401 |
2015 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined RNAi of Lp-PLA2 and YKL-40 is superior to RNAi of Lp-PLA2 or YKL-40 alone in ameliorating atherosclerosis.
|
30138439 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The association of Lp-PLA2 activity with oxLDL/LDL suggests that Lp-PLA2 may be a modulating factor in the process of atherosclerosis.
|
16438975 |
2006 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the first biomarker for predicting stroke risk associated with atherosclerosis (lipoprotein-associated phospholipase A2) was recently approved by the United States Food and Drug Administration.
|
16822391 |
2006 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a promising therapeutic target for atherosclerosis, Alzheimer's disease, and diabetic macular edema.
|
29193967 |
2017 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Considerable discussion continues regarding the precise role that secreted lipoprotein-associated phospholipase A2 (Lp-PLA2), also called platelet-activating factor acetylhydrolase, plays in atherosclerosis.
|
15990594 |
2005 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results uncover a new link between oxLDL and lp-PLA2, and may provide insight into this interaction in the context of atherosclerosis.
|
19910444 |
2010 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of the lipoprotein-associated phospholipase A(2) gene (PLA2G7) in atherosclerosis remains controversial.
|
21834908 |
2011 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations provide a rationale to explore whether inhibiting Lp-PLA2 activity and consequent interference with the formation of bioactive lipid mediators will abrogate inflammation associated with atherosclerosis, produce favorable changes in intermediate cardiovascular end points (eg, biomarkers, imaging, and endothelial function), and ultimately reduce cardiovascular events in high-risk patients.
|
15731492 |
2005 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is being evaluated as a therapeutic target for treatment of atherosclerosis.
|
23439604 |
2013 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These patients had a higher iEAT, and their HDL contained less cholesterol and more apoA-II and lipoprotein-associated phospholipase A2 than patients without subclinical atherosclerosis.
|
30526614 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discussed in this review is the accumulating evidence supporting the view that Lp-PLA2 is a potential biomarker of coronary heart disease and plays and an important proinflammatory role in the progression of atherosclerosis.
|
11963798 |
2002 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
LHGDN |
Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle.
|
12428682 |
2002 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Objective To evaluate the association between plasma lipoprotein-associated phospholipase A2 (Lp-PLA2; known to release inflammatory mediators that promote atherosclerosis) and coronary heart disease (CHD) in Chinese patients.
|
28222638 |
2017 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, disagreement continues to exist regarding the validity of Lp-PLA(2) as an independent marker of atherosclerosis and a scientifically justified target for intervention.
|
22665167 |
2012 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lp-PLA(2) is an enzyme with potentially multiple risks in atherosclerosis.
|
12865731 |
2003 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an enzyme which binds to oxidized LDL and has a pro-inflammatory role in the pathogenesis of atherosclerosis.
|
21870060 |
2011 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, long-term inhibition of endogenous Lp-PLA2 activity with darapladib was not associated with a change in plaque progression and vulnerability indices after 6 months of therapy, and the endogenous Lp-PLA2 pathway may not play a direct role in the progression of early atherosclerosis in humans.
|
29135482 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we evaluated the effects of a specific lp-PLA2 inhibitor on atherosclerosis in ApoE-deficient mice and its associated mechanisms.
|
21909350 |
2011 |